NCT01762787 - Phase I Methodology Study to Validate the Cantharidin Blister Model in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 17, 2010

Primary Completion Date

January 14, 2011

Study Completion Date

January 14, 2011

Conditions

Inflammation

Interventions

DRUG

Cantharidin solution

5 microlitres of 0.025 to 0.5% topically on Day 1, 2 and 3

DRUG

Aspirin

300mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only

DRUG

Prednisolone

30mg orally once a day over a course of 4 days (starting Day -3) Part 2 only

DRUG

Placebo to aspirin

0mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only

DRUG

Placebo to prednisolone

0mg orally once a day over a course of 4 days (starting Day -3) Part 2 only

Trial Locations (1)

GSK Investigational Site, Cambridge